Genetic testing for cardiomyopathy is a laboratory test that looks for DNA changes linked to diseases of the heart muscle. A blood or saliva sample is usually used. The result may help explain why cardiomyopathy developed, guide care, and show which relatives may benefit from testing or heart checks. It does not detect every cause, and results need to be interpreted alongside personal and family medical history.
Why is genetic testing used for cardiomyopathy?
Cardiomyopathy is a group of conditions that affect the heart muscle. These conditions can change the heart's size, thickness, structure, or ability to pump blood. Some forms develop because of inherited genetic changes, while others have different causes.
Genes contain instructions that help the body grow and function. A genetic change, also called a genetic variant, can affect how a heart muscle protein works and may contribute to cardiomyopathy. Genetic testing examines selected genes for variants associated with these conditions.
According to the American College of Cardiology, genetic testing can help clarify the possible cause of cardiomyopathy, support decisions about care, and guide screening plans for relatives. It is considered alongside the person's medical history, heart examinations, and other clinical findings rather than used as a standalone test.
Who may benefit from genetic testing?
A cardiologist or another qualified healthcare professional may discuss genetic testing when a person's medical history or family pattern suggests that cardiomyopathy could be inherited. Testing may be useful in several situations:
- A person has been diagnosed with a type of cardiomyopathy that may have a genetic cause.
- Several relatives have cardiomyopathy or unexplained heart muscle disease.
- There is a known disease-associated genetic variant in the family.
- A family history includes unexplained sudden cardiac death or certain heart rhythm problems that raise concern about an inherited heart condition.
- A healthcare professional suspects an inherited cardiomyopathy even though the person has not developed noticeable symptoms.
Genetic testing is not necessary for every person with cardiomyopathy. The decision depends on the type of heart condition, the clinical findings, the family history, and whether the result could help guide care or family screening.
How does genetic testing for cardiomyopathy work?
The process usually begins with a discussion of the person's health and family history. A healthcare professional may ask about relatives with cardiomyopathy, heart failure, abnormal heart rhythms, or unexplained early deaths. Reviewing this information helps determine whether genetic testing is appropriate and which genes should be examined.
1. Genetic counseling before testing
Before testing, a genetic counselor or appropriately trained healthcare professional can explain what the test examines, what the possible results mean, and how those results might affect family members. Counseling also provides an opportunity to discuss limitations, privacy concerns, costs, and the possibility of receiving an uncertain result.
2. Collecting a sample
Testing commonly uses a blood or saliva sample. The sample is sent to a laboratory, where specialists examine selected genes for genetic variants associated with cardiomyopathy. The procedure for collecting the sample is generally straightforward and does not require surgery or a heart biopsy.
3. Examining genes linked to heart muscle disease
The laboratory may examine a group of genes in a single test, known as a multigene panel. The genes included depend on the suspected type of cardiomyopathy and the person's clinical findings. In some circumstances, a more focused genetic test or a broader genetic analysis may be considered. The American College of Cardiology identifies multigene panel testing as a general first-line approach for investigating many cardiomyopathies, with the choice of test guided by individual circumstances.
4. Reviewing the results
Once the laboratory report is available, a healthcare professional interprets it in the context of the person's diagnosis, examination results, and family history. For some tests, results may be available within a few weeks, although the time varies by laboratory and the type of analysis performed. A follow-up discussion is important because a genetic report can contain findings that are difficult to interpret without clinical context.
What do cardiomyopathy genetic test results mean?
A genetic report generally classifies identified variants according to how strongly the available evidence links them to disease. The main categories help distinguish a potentially disease-causing finding from one that is harmless or not yet understood.
Pathogenic or likely pathogenic variant
A pathogenic variant is considered disease-causing, while a likely pathogenic variant has strong evidence suggesting that it causes disease. If a relevant variant is identified, it may explain an inherited form of cardiomyopathy and allow relatives to be offered testing for that specific change. However, finding the variant does not necessarily establish how severely a person will be affected or when signs of the condition might develop.
Variant of uncertain significance
A variant of uncertain significance (VUS) is a DNA change for which there is not enough evidence to determine whether it contributes to disease. The National Human Genome Research Institute explains that additional evidence, including information about the variant in other family members, may help clarify its significance.
An uncertain result does not confirm that a genetic change causes cardiomyopathy. It should not be treated as equivalent to a pathogenic result when making decisions about relatives. The classification may change as more scientific evidence becomes available, so the healthcare team can advise whether future review is appropriate.
Negative result
A negative result means the test did not identify a disease-causing variant among the genetic changes it examined. This may be reassuring in some circumstances, but it does not rule out every inherited cause of cardiomyopathy. A disease-associated variant may remain unidentified, or the test may not detect the genetic explanation for a particular person's condition.
When the result is negative, the medical and family history still matter. Heart examinations and screening for relatives may remain appropriate, particularly when the family's clinical history suggests an inherited condition.
Benign or likely benign variant
A benign or likely benign variant is considered unlikely to cause the condition being investigated. Such a finding generally does not explain cardiomyopathy or establish an inherited risk for the disease on its own. The overall report should be reviewed with a healthcare professional to understand which findings, if any, are medically relevant.
How can genetic testing help family members?
When testing identifies a disease-associated variant in a person with cardiomyopathy, relatives may be offered targeted testing to determine whether they carry the same variant. This is often called cascade genetic testing. It usually begins with close biological relatives, including parents, siblings, and children, and may extend to other family members depending on the results and family history.
The American Heart Association explains how identifying the genetic cause of hypertrophic cardiomyopathy can help families determine which relatives may benefit from testing. The same general principle of targeted family testing is used for other inherited cardiomyopathies when an informative disease-associated variant has been established.
If a relative tests positive for a relevant variant, it does not necessarily mean that the person already has cardiomyopathy or will develop it in the same way as another family member. The next steps depend on the specific condition and the variant involved. A healthcare professional may recommend heart assessments, such as an electrocardiogram (ECG) or echocardiogram, and further monitoring when appropriate.
If no disease-associated variant is identified in the person first tested, relatives may still need clinical screening based on their family history. Genetic testing and heart screening serve different purposes: genetic testing looks for particular DNA changes, while heart assessments evaluate the structure and function of the heart.
Can children have genetic testing for cardiomyopathy?
Yes. Genetic testing may be considered for children when an inherited cardiomyopathy is suspected or a disease-associated variant is known in the family. Some inherited heart conditions can affect people during childhood, while others may not become apparent until adulthood. The appropriate timing of testing depends on the specific condition and whether the information could guide medical care or screening.
Families can discuss the benefits, limitations, and possible emotional effects of testing with a pediatric cardiologist or genetic counselor. If a child has a family history of cardiomyopathy, the healthcare team can also advise whether heart assessments are needed, even before genetic test results are available.
What are the limitations of genetic testing?
Genetic testing can provide valuable information, but it cannot answer every question about cardiomyopathy. Not all cases have an identified genetic cause, and the meaning of a particular variant may be uncertain. Even when a disease-associated variant is found, the result may not predict the age at which a condition will develop or its future course in an individual.
Testing also does not replace clinical evaluation. A cardiologist may still recommend an ECG, echocardiogram, or other investigations to assess the heart. The American Heart Association notes that genetic testing may help identify cardiomyopathy-related changes in families, including in people who do not yet show signs or symptoms. This is one reason genetic results are interpreted alongside clinical findings rather than on their own.
What should you discuss with your healthcare professional?
Before deciding whether to have genetic testing, consider asking which type of cardiomyopathy is suspected, which genes the test examines, and how different results could affect your care. It is also useful to discuss whether relatives should be screened, whether a negative result would change the family's screening plan, and what support is available for interpreting uncertain findings.
Ask about the expected cost, insurance or other coverage arrangements, and how genetic information will be stored and shared. If you already have a genetic test report from a relative, bring a copy to the appointment when possible. The report may help the healthcare team decide whether targeted testing would be more informative than a new broad panel.
Genetic testing is most useful when the results are connected to a clear plan for interpreting findings, guiding appropriate clinical care, and supporting relatives who may benefit from screening.